While some promising new treatments for breast cancer are years away from regular treatment regimens, others are on the market or just around the corner.
Still on the horizon for treating breast cancer are anti-angiogenesis drugs. They block the formation of new blood vessels that feed tumors and help them grow. These drugs have shown promise in treating colon cancer and are now being studied in patients with advanced breast cancer. But it may be some time before these drugs have been studied enough to make the leap to treating early-stage breast cancer.
Elyse Caplan remembers it well, that first conversation with her oncologist. She had just been diagnosed with stage IIB breast cancer, and they were discussing the game plan for treatment. If her oncologist mentioned "recurrence" -- the possibility that her cancer could return -- it was lost on her, she says.
"You sit through an hour-long appointment and take notes, but when the doctor says one thing that's very upsetting, you just freeze," she tells WebMD. "You're thinking, 'I'm going to lose my...
Even so, new breast cancer treatments are available now. Over the past year, doctors have learned a lot more about many targeted therapies that very soon may be helping millions of women live longer and healthier lives after learning they have breast cancer.
Abraxane and Albumin-Bound Nanoparticle Drugs
In January, headlines trumpeted the release of a new chemotherapy drug for breast cancer called Abraxane. Technically, Abraxane isn't a new drug -- it's an exciting new way of delivering an existing drug.
Paclitaxel, commonly marketed as Taxol or Taxotere, is part of many chemotherapy drug regimens, but it has one big problem, says Clifford Hudis, chief of the Breast Cancer Medicine Service at New York's Memorial Sloan-Kettering Cancer Center. "It doesn't dissolve in water, which means we have to put the drugs in solvents to deliver them to patients." Those solvents can cause a number of side effects, including severe allergic reactions. Patients taking paclitaxel have to receive heavy doses of other medications first, such as steroids and antihistamines, before getting their chemotherapy.
Abraxane does a neat end run around that problem. A process called protein-bound nanoparticle technology creates tiny particles that bind the paclitaxel to a naturally occurring protein called albumin. "The binding makes little packets of paclitaxel -- think of them as little bubbles -- that can be dissolved in water," says Hudis. This means no more solvent, which in turn means no more medications before chemotherapy, and no more of the side effects that go along with them. It's also shortened the chemotherapy's infusion time from more than three hours to around half an hour.